Member Info for ChrisToffer

Very good point, Here's Sir John Bell saying they haven't kept pace with antivirals and now needs to be a major focus,

https://www.youtube.com/watch?v=4sbqXgWzhEU (4.40mins)

Great day today. This was foretold in the Senate back in November (which is available for all to see on Google) so it should be no surprise. I simply drew attention to the fact and tried to keep the conversation alive. It was clear that it should be the news that finally puts SNG001 on the map.

Thanks everyone for the kind messages. I am just happy people held on and now is the time to enjoy the ride. EUA is hopefully the next stop.

I left LSE to simply take a break. It has been a long six months.

Org - I blocked you because you annoy me. I am not your mother.
Dumbpunter- you need to concentrate on trying to understand basic trial data.

Cheerio and best of luck to everyone!

pmjh

It opens to more investors in the event they want to raise captial by issuing shares. However they have now secured funding for activ 2 through NIAID so no need for funding there and any whiff o f success on either of the trials will mean a pre-order which will far exceed any fundraising anyway.

So no need to to move markets

Dumbpunter, you're suggesting the company paid someone to come onto this board and share information that was in the public domain with 100's of people ahead of company announcements?

What planet do you live on?

The trial is blinded and P2 is for 'up to a maximum of 220' patients which means, unlike any SNG001 trials up to this point, they'll be watching the results as they come in.

Things are going to move very fast from .

I suspect it'll if we get any mention it'll come from Fauci. He's the director of NIAID. May not get a word in with all the Trump bashing though.

This was indeed one of the first pieces of evidence that indicated SNG001 would be on activ 2.

The same Dr.Jha that wrote it is quoted in this article, https://www.google.com/amp/s/www.usnews.com/news/politics/articles/2021-01-22/fauci-unleashed-doc-takes-liberating-turn-at-center-stage%3fcontext=amp

''Clarity of message is the most important thing the government can be doing right now; the single biggest disservice Trump did was constantly telling people that pandemic was about to be over,” said Dr. Ashish Jha, dean of the Brown University School of Public Health, who has known Fauci for more than 20 years.

https://clinicaltrials.gov/ct2/show/NCT04443868

This trial is for 50 patients. Long Long way to go.

And just like that, 2 nassimis in the filter bin!

Reported too

Scinv filtered - blocking up the board with the same sheeite over and over.

Thanks Duke! Here's the video https://www.bloomberg.com/news/videos/2021-01-21/fauci-says-u-s-to-join-covax-re-engage-with-who-video

IHWB filtered

A lot of you are missing the point by focusing on the timeline to readout. If another 120 patients were enough for an approval then the company would have been fully focused on the home trial over the last few months. Instead they've implemented the P3 and are potentially about to start on Activ 2.

RM doesn't even mention results in his comment, it's all about confirming feasability and that further supports the case for inclusion on Activ 2. If they do get on Activ 2 then an active DMC could see the drug approved even before these results.

Tommy, there needs to be a DMC in place from the outset. Look at line E.8.7 and you will see there wasn't. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB

There is on SG018 and there is on Activ 2.

Tommy, there is no DMC in the SG016 trial so we'll have to wait on these results. The RNS actually places more emphasis on the importance of proving the feasibility of remote trial and drug administration. Its set up perfectly now for Activ 2 and i wouldn't be surprised if the DMC on that trial overtakes the SG016 analysis.

RM spoke about collaboration between the Home and Principle trials back in November.

The company have not announced inclusion of Activ 2 and neither have NIH so its highly unlikely that progress in the US is priced in.

1 in 20 people = over 19 million in the UK and US alone. Hardly a small minority, and thats the bare minimum.

Doc, if the Syn press office set up an at home follow up for a patient in a double blind placebo controlled trial they will completely undermine their own dataset.

Anyone who thinks this should be publicised needs to wake up, leave the patient alone and let the company get on with completing the trial.

Kessler, "95% vaccinations sounds good but that still leaves 1 in 20 people at risk, there are people who are immuno suppressed, there are going to be other viruses; we know that."